

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Lonsurf

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	THORIC.
Group Number:	NPI:	State Lic ID:
Address:	Address:	Oldic Elo ID.
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
g qu	ootiono una oigin	
Q1. Please provide the ICD diagnosis code for the above condition.		
Q2. For what diagnosis is this drug being prescribed (pick one)?		
☐ Metastatic Colorectal Cancer (CRC)		
☐ Other		
Q3. If you selected "other" in question 2, please provide documentation that use is consistent with a category 1 or higher recommendation per NCCN compendia or guidelines.		
Q4. Is prescribing physician a hematology or oncology spe	cialist?	
☐ Yes ☐ No		
Q5. If CRC, has the patient previously been treated with a fluoropyrimidine-based chemotherapy?		
☐ Yes ☐ No		
Q6. If CRC, has the patient previously been treated with an oxaliplatin-based chemotherapy?		
☐ Yes ☐ No		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Lonsurf

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
Patient Name:	Supervising Physician:
Q7. If CRC, has the patient previously been treated with ar	n irinotecan-based chemotherapy?
☐ Yes ☐ No	
Q8. If CRC, has the patient previously been treated with ar	n anti-VEGF biological therapy?
☐ Yes ☐ No	
Q9. If CRC, is the patient RAS wild type?	
☐ Yes ☐ No	
Q10. If patient is RAS wild type, have the patient been trea	ted with an anti-EGFR therapy?
☐ Yes ☐ No	
Q11. Additional Comments:	
Prescriber Signature	Date
□ Expedited/Urgent - By checking this box and signing above	e. I certify that applying the standard review timeframe may
seriously jeopardize the life or health of the enrollee or the en	
	ssity denial. Requesting providers may speak to a SWHP pharmacist in opportunity to help impact the decision on a request before coverage

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document